First dual-drug liposomal encapsulation of daunorubicin and cytarabine shown to…
Deliver superior overall survival vs 7+3a to adults with newly-diagnosed t-AML or AML-MRC1
Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial1
Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC. See full study design.
Safety and effectiveness of VYXEOS in pediatric patients have not been established.
VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).